利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.014 秒)

    7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
    3.
    发明授权
    7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD) 有权

    公开(公告)号：US10039724B2

    公开(公告)日：2018-08-07

    申请号：US15321778

    申请日：2015-06-29

    申请人： GW Pharma Limited

    发明人： Colin Stott ,  Marnie Duncan ,  Vincenzo Di Marzo ,  Cristoforo Silvestri ,  Andrea Martella

    IPC分类号： A61K31/05

    摘要： The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.

    Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
    4.
    发明授权
    Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer 有权

    公开(公告)号：US09962341B2

    公开(公告)日：2018-05-08

    申请号：US15321766

    申请日：2015-06-26

    申请人： GW Pharma Limited

    发明人： Colin Stott ,  Marnie Duncan ,  Thomas Hill

    IPC分类号： A61K31/05

    CPC分类号： A61K31/05 ,  A61K2300/00

    摘要： The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).

    THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA
    5.
    发明申请
    THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA 审中-公开
    使用PHYTOCANNABINOIDS治疗OVARIAN CARCINOMA

    公开(公告)号：US20160136128A1

    公开(公告)日：2016-05-19

    申请号：US14899613

    申请日：2014-06-19

    申请人： GW Pharma Limited ,  OTSUKA PHARMACEUTICAL CO. LIMITED

    发明人： Farideh Javid ,  Marnie Duncan ,  Colin Stott

    IPC分类号： A61K31/352 ,  A61K31/192 ,  A61K36/185 ,  A61K31/05

    CPC分类号： A61K31/352 ,  A61K31/05 ,  A61K31/192 ,  A61K31/353 ,  A61K36/185 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.

    摘要翻译： 本发明涉及植物大麻素在卵巢癌的治疗中的应用。 优选地，植物大麻素选自：大麻二酚（CBD）; 大麻二酸（CBDA）; 大麻素（CBG）; 大麻酚酸（CBGA）; 大麻素丙基变体（CBGV）; 和四氢大麻素（THCV）。 在另一个实施方案中，一种或多种植物大麻素相互组合使用。 大麻素的组合优选由CBD和CBG组成。

    ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER
    7.
    发明申请
    ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER 有权

    公开(公告)号：US20170143642A1

    公开(公告)日：2017-05-25

    申请号：US15321766

    申请日：2015-06-26

    申请人： GW Pharma Limited

    发明人： Colin Stott ,  Marnie Duncan ,  Thomas Hill

    IPC分类号： A61K31/05

    CPC分类号： A61K31/05 ,  A61K2300/00

    摘要： The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).

    7-HYDROXY CANNABIDIOL (7-OH-CBD) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    8.
    发明申请
    7-HYDROXY CANNABIDIOL (7-OH-CBD) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 有权

    公开(公告)号：US20170128385A1

    公开(公告)日：2017-05-11

    申请号：US15321778

    申请日：2015-06-29

    申请人： GW Pharma Limited

    发明人： Colin Stott ,  Marnie Duncan ,  Vincenzo Di Marzo ,  Cristoforo Silvestri ,  Andrea Martella

    IPC分类号： A61K31/05

    CPC分类号： A61K31/05

    摘要： The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.

    TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING
    9.
    发明申请
    TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING 有权
    四氢生物素在治疗鼻炎和呕吐中的应用

    公开(公告)号：US20160074357A1

    公开(公告)日：2016-03-17

    申请号：US14785055

    申请日：2014-04-14

    申请人： GW Pharma Limited

    发明人： Erin Rock ,  Linda Parker ,  Marnie Duncan ,  Colin Stott

    IPC分类号： A61K31/352

    CPC分类号： A61K31/352 ,  A61K2300/00

    摘要： The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.

    摘要翻译： 本发明涉及四氢大麻素（THCV）用于治疗恶心和呕吐的用途。 优选地，大麻植物提取物分离和/或纯化THCV。 优选地，恶心和/或呕吐是由药物如化学治疗剂的作用引起的。